Clinical Trial Update: Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating refametinib in combination with sorafenib in RAS-mutant hepatocellular carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Refametinib (refametinib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED